Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

GK Abou-Alfa, D Niedzwieski, JJ Knox, A Kaubisch… - 2016 - ascopubs.org
192 Background: An exploratory analysis of a randomized phase II study in HCC comparing
doxorubicin (D) alone to doxorubicin plus sorafenib (D+ S) showed a significant …
被引用次数：140 相关文章

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

GK Abou-Alfa, D Niedzwieski, JJ Knox… - Journal of Clinical …, 2016 - cir.nii.ac.jp
抄録< jats: p> 192</jats: p>< jats: p> Background: An exploratory analysis of a randomized
phase II study in HCC comparing doxorubicin (D) alone to doxorubicin plus sorafenib (D+ S) …

[引用][C] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

GK Abou-Alfa, D Niedzwieski, JJ Knox… - Journal of Clinical …, 2016 - cir.nii.ac.jp
Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with
advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). | CiNii Research CiNii …